2019 International Congress

Monday, September 23, 2019

1:45pm-3:15pm

The cognitive profiles differ among freezing of gait subtypes in Parkinson’s disease

J. Longhurst, J. Caldwell, A. Ritter, V. Mishra, B. Bluett, M. Landers (Las Vegas, NV, USA)

Other  ·  Agora 2 West, Level 2

1:45pm-3:15pm

The comparison of the clinical characteristics and treatment outcomes between non-troublesome and troublesome hemifacial spasm in 270 Thai patients

T. Sangpeamsook, Y. Pitakpatapee, A. Suengtaworn, J. Srikajon, P. Srivanitchapoom (Bangkok, Thailand)

Myoclonus  ·  Les Muses, Level 3

1:45pm-3:15pm

The costs of caregiving in Parkinson’s disease

S. Horn, S. Wu, Y. Dai, F. Cubillos, N. Dahodwala (Miami, FL, USA)

Caregiver Burden  ·  Les Muses Terrace, Level 3

1:45pm-3:15pm

The distinct pattern of movement disorders in Caspr2 and LGI1 antibody associated autoimmune encephalitis

F. Gövert, J. Becktepe, B. Balint, J. Varley, S. Irani, M. Titulaer, J. de Vries, B. Joubert, J. Honnorat, H. Ariño Rodríguez, J. Dalmau, G. Deuschl, F. Leypoldt (Kiel, Germany)

Myoclonus  ·  Les Muses, Level 3

1:45pm-3:15pm

The effect of ADORA2A gene polymorphism on the dyskinesia of Parkinson’s Disease

BC. Ari, F. Mayda Domac, G. Ozgen Kenangil, N. Imamova, A. Cinar Kuskucu (Istanbul, Turkey)

Genetics  ·  Les Muses Terrace, Level 3

1:45pm-3:15pm

The effect of ATP13A2/PARK9 levels on a-syn spreading in mice brains

T. Tsunemi, Y. Ishiguro, A. Okuzumi, A. Yoroisaka, N. Nukina, N. Hattori (Tokyo, Japan)

Rare Genetic and Metabolic Diseases  ·  Les Muses Terrace, Level 3

1:45pm-3:15pm

The Effect of Gocovri on Motor Aspects of Experiences of Daily Living: Analyses of MDS-UPDRS Part II Data from a Phase 3 Program

R. Hauser, D. Kremens, D. Chernick, R. Patni, J. Hubble (Tampa, FL, USA)

Clinical Trials, Pharmacology and Treatment  ·  Agora 3 West, Level 3

1:45pm-3:15pm

The effect of intranasal oxytocin in patients with functional motor symptoms: an open label case series

B. Demartini, D. Goeta, D. Di Benedetto, A. Casiraghi, D. Mazza, A. Priori, O. Gambini (Milano, Italy)

Functional (Psychogenic) Movement Disorders  ·  Les Muses Terrace, Level 3

1:45pm-3:15pm

The effect of levodopa on speech in advanced Parkinson’s Disease: acoustic analysis and correlation with motor features and dyskinesia

F. Cavallieri, C. Budriesi, A. Gessani, V. Fioravanti, E. Menozzi, S. Contardi, F. Valzania, F. Antonelli (Reggio Emilia, Italy)

Other  ·  Agora 2 West, Level 2

1:45pm-3:15pm

The effect of levodopa-carbidopa intestinal gel relative to optimized medical treatment on dyskinesia: Design and baseline characteristics for an open-label, randomized multicenter 12-week study in advanced Parkinson’s disease patients (DYSCOVER Study)

E. Alvarez, C. Spanaki, E. Pekkonen, L. Manzanares, Y. Liu, O. Sánchez-Soliño, L. Barbato (Elche, Spain)

Clinical Trials, Pharmacology and Treatment  ·  Agora 3 West, Level 3